Bausch Health Companies Inc. Impairment of Intangible Assets, Finite-lived
Bausch Health Companies Inc. (BHC) reported Impairment of Intangible Assets, Finite-lived of $14.00 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2022-11-03
- Bausch Health Companies Inc. impairment of intangible assets, finite-lived for the quarter ending 2022-06-30 was $6.00M, a 87.23% decline year-over-year.
- Bausch Health Companies Inc. impairment of intangible assets, finite-lived for the quarter ending 2022-03-31 was $8.00M, a 94.59% decline year-over-year.
- Bausch Health Companies Inc. impairment of intangible assets, finite-lived for the quarter ending 2021-09-30 was $18.00M, a 800.00% increase year-over-year.
- Bausch Health Companies Inc. impairment of intangible assets, finite-lived for the quarter ending 2021-06-30 was $47.00M, a 4600.00% increase year-over-year.
- Bausch Health Companies Inc. impairment of intangible assets, finite-lived for fiscal 2019 was $5.00M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2022-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $14.00M 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $8.00M 10-Q · filed 2022-05-10 | |||
| 2021-09-30 | $18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $65.00M derived: sum of 2 quarters · filed 2022-11-03 | $213.00M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $47.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $195.00M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $148.00M 10-Q · filed 2022-05-10 | |||
| 2020-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $3.00M derived: sum of 2 quarters · filed 2021-11-02 | $17.00M 10-Q · filed 2021-11-02 | -$27.00M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $15.00M 10-Q · filed 2021-08-03 | -$29.00M derived: sum of 3 quarters · filed 2021-08-03 | $4.00M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $14.00M 10-Q · filed 2021-05-04 | -$30.00M derived: sum of 2 quarters · filed 2021-05-04 | $3.00M derived: sum of 3 quarters · filed 2021-05-04 | |
| 2019-12-31 | -$44.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | -$11.00M derived: sum of 2 quarters · filed 2020-11-03 | $5.00M 10-K · filed 2020-02-19 | |
| 2019-09-30 | $33.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $49.00M 10-Q · filed 2020-11-03 | ||
| 2019-06-30 | $16.00M 10-Q · filed 2020-08-06 | |||
| 2017-06-30 | $44.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $80.00M 10-Q · filed 2018-08-07 | $118.00M derived: sum of 3 quarters · filed 2018-08-07 | $260.00M derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | $36.00M 10-Q · filed 2018-05-08 | $74.00M derived: sum of 2 quarters · filed 2018-05-08 | $216.00M derived: sum of 3 quarters · filed 2018-05-08 | $431.00M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $38.00M 10-K · filed 2017-03-01 | $180.00M derived: sum of 2 quarters · filed 2017-03-01 | $395.00M derived: sum of 3 quarters · filed 2017-03-01 | $411.00M derived: sum of 4 quarters · filed 2017-03-01 |
| 2016-09-30 | $142.00M 10-K · filed 2017-03-01 | $357.00M derived: sum of 2 quarters · filed 2017-03-01 | $373.00M derived: sum of 3 quarters · filed 2017-03-01 | $452.00M derived: sum of 4 quarters · filed 2017-03-01 |
| 2016-06-30 | $215.00M 10-K · filed 2017-03-01 | $231.00M derived: sum of 2 quarters · filed 2017-03-01 | $310.00M derived: sum of 3 quarters · filed 2017-03-01 | $336.00M derived: sum of 4 quarters · filed 2017-03-01 |
| 2016-03-31 | $16.00M 10-Q · filed 2016-11-09 | $95.00M derived: sum of 2 quarters · filed 2016-11-09 | $121.00M derived: sum of 3 quarters · filed 2016-11-09 | |
| 2015-12-31 | $79.00M 10-Q · filed 2016-11-09 | $105.00M derived: sum of 2 quarters · filed 2016-11-09 | ||
| 2015-09-30 | $26.00M 10-Q · filed 2015-10-26 | |||
| 2013-03-31 | $22.20M 10-Q · filed 2013-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |